MLabs Evaperties Delivered Personally

Patient Address

Bill To:

Address

Policy Holders Name

Policy Holders Name

☐ STAT PROCESSING

Collection Date:

HEMATOPATHOLOGY CONSULT REQUISITION

7IP

Country

University of Michigan Health System Department of Pathology - MLabs UH 2F361 • 1500 E. Medical Center Drive Ann Arbor, MI 48109-5054 734-936-2598 • 800-862-7284

☐ Client/Referring Institution

☐ Medicare = ☐ In Patient on DOS ☐ O

City

Prima

☐ Pa

Time:

	Client	Patient Reg or M	IRN:						
		Patient Name:	Last	First	MI				
	Ward	Birthdate:		Gender: OM OF					
		Ordering Doctor	:Last	First	NPI#				
State ZIP Home Phone #									
ry In	surance (Card Nam	e) Prima	ry Policy/Contract #	Primary Group #	Policy Holders DOB				
ndary Insurance (Card Name) Secondary Policy/Contract # Secondary Group # Policy Holders DO									
tient/Insurance			If patient or insurance information is not included or attached to this form, your facility will be billed. For Medicare patients classified as a hospital inpatient or						
ut Patient on DOS			outpatient on the date of service, charges must be billed to the referring client.						

State

ICD-10 CODES

ICD-10 Codes are required for billing. When ordering tests for which reimbursement will be sought order only tests that are medically necessary for the diagnosis and treatment of the patient.

REFERRING PHYSICIAN TO BE CONTACTED WITH RESULTS AND/OR QUESTIONS
Referring Physician

Referring Institution

Phone

Fax

City

This request to order tests from MLabs certifies to MLabs that (1) the ordering physician has obtained written informed consent from the patient as required by applicable state or federal laws for each test ordered and (2) the ordering physician has authorization from the patient permitting MLabs to report results for each test ordered to the ordering physician.

(Oam Opm) Footnote: Case/Accn #

MATERIALS SENT EXTRACTED DNA (PLEASE INDICATE SOURCE):								
\square Bone Marrow Asp. \square Na Heparin(G) green #	☐ EDTA(L) lavender # ☐ Fresh Tissue ☐ Fluid		Other source	_ □ Paraffin Block #				
☐ Peripheral Blood ☐ Na Heparin(G) green #	☐ H & E Slides #							
PATIENT HISTORY/DIAGNOSIS (REQUIRED)	PATIENT STATUS: NEW	DIAGNOSIS RELAP	SE MONITORING	☐ MIN. RESIDUAL DISEASE				
□ Non-Hodgkin Lymphoma(NHL) B-Cell T-Cell Follicular Lymphoma Mantle Cell Lymphoma MALT Lymphoma Burkitt vs Large B-Cell □ Plasma Cell Dyscrasia/Multiple Myeloma □ Hodgkin Lymphoma □ Chronic Lymphoproliferative Disorders CLL/SLL Hairy Cell Leukemia (HCL)	□ Acute Leukemia □ AML □ ALL □ APL □ Myeloproliferative Disorders (MPD) □ CML □ PV □ ET □ Myelodysplastic Syndrome (MDS) □ CMMoL	☐ PNH ☐ Reactive Hyperplasia ☐ Cytopenias ☐ LAD ☐ Leukocytosis ☐ NOS/Other	TREATMENT □ None □ Current □ >1 Month ago □ Induction days ago □ Radiotherapy	CHEMOTHERAPY Rituxan® Campath® GCSF Gleevec® GMCSF EPO Other:				

CONSULTATIVE SERVICES FLOW CYTOMETRY ☐ KIT D816V Mutation T, L ☐ COMPREHENSIVE PRIMARY DIAGNOSIS ON REFERRED Send copy of most recent WBC, platelet and differential (CBC). ☐ KIT Mutation for AML - Exons 8, 17 T, L CSF specimens please include copy of fluid count and differential. SPECIMENS: Bone marrow study includes: bone marrow ☐ PML/RARA t(15;17) Translocation (PCR) Qualitative T, L morphology evaluation, Cytogenetics evaluation, and \square Leukemia / Lymphoma Panel to be determined F. TR. G by testing laboratory MYELOPROLIFERATIVE NEOPLASMS (MPN) / CML triage for Flow Cytometry and/or Molecular Diagnostics F, TR, G studies if indicated. ☐ Panel 1: Stem cell neoplasm/Acute Leukemia ☐ JAK2 V617F Mutation REQUIRED: BM clot, BM core biopsy, 5 BM aspirate ☐ Panel 2: Mature Lymphoid Leukemia/ F, TR, G If JAK2 V617F is negative, perform: ☐ CALR ☐ MPL ☐ JAK2 Exon 12 L smears, 3 PB smears, BM in 3 green tops (G), BM in 1 Non-Hodgkin Lymphoma (without plasma cells) ☐ JAK2 Exon 12 Mutation ☐ LGL/NK markers ☐ HCL markers lavender top (L), copy of most recent complete blood cell ☐ CALR Mutation L F, TR, G ☐ Panel 3: Plasma Cell/Multiple Myeloma and platelet count (CBC). ☐ MPL Mutation ☐ Panel 4: Comprehensive F, TR, G ☐ KIT D816V Mutation T. L ☐ AUTHORIZATION: In addition to what has been ordered, (combined panels 1, 2 without plasma cells) ☐ BCR/ABL1 Analysis, Quantitative the UMHS Pathologist is authorized to addother testing ☐ Panel 5: Cutaneous T-cell Lymphoma G (PB only) ☐ BCR/ABL1 Kinase Domain Mutation 1 as needed to assist in evaluation. (T-cell subsets and pan T-cell epitopes only) ☐ Panel 6: Mastocytosis G (BM only) **LYMPHOMA** ☐ Panel 7: Rituximab G (PB only) ☐ B Cell Clonality (IGH & IGK Gene Rearrangement) CYTOGENETICS T, L ☐ Panel 8: Paroxysmal Nocturnal ACD - soln A ☐ B Cell Clonality (IGH Gene Rearrangement) T, L ☐ Chromosome Analysis (Culture and Karyotype) G Hemoglobinuria (PNH) or soln B (PB only) ☐ B Cell Clonality (IGK Gene Rearrangement) T, L ☐ Cancer Cytogenomics Array G. TR T, L ☐ T Cell Clonality (TRG & TRB Gene Rearrangement) ☐ HOLD until notified by client ☐ T Cell Clonality (TRG Gene Rearrangement) T. L **FISH ONCOLOGY PROBES** G (Please contact MLabs (800-862-7284) by 12 noon day after submission ☐ T Cell Clonality (TRB Gene Rearrangement) \square BCR/ABL[t(9:22)] ☐ PML/RARA [t(15;17)] to ensure optimal specimen viability for flow cytometry analysis) T, L ☐ IGH/BCL2 t(14;18) Translocation (PCR) T, L ☐ CLL Panel ☐ Eosinophilia Panel S, T **MOLECULAR DIAGNOSTICS** ☐ IGH/BCL2 t(14;18) Translocation (FISH) ☐ IGH/CCND1 [t(11:14)] **ACUTE MYELOID LEUKEMIA** ☐ BCL6 (3q27) Rearrangement (FISH) S, T The following FISH require an additional green top: □ NPM1 Mutation □ □ CEBPA □ FLT3 Mutation ☐ MYC (8g24) Rearrangement (FISH) S, T if NPM1 & FIT3 T, L ☐ Multiple Myeloma Panel MML PCPDF G are both negative ☐ MALT1 (18q21) Rearrangement (FISH) S, T L ☐ Myelodysplastic Syndrome Panel MML MDSF ☐ MYD88 (L265P) Mutation S, T, L ☐ CEPBA Mutation 1 ☐ BRAF V600E/V600K Mutations ☐ IDH1 and IDH2 Mutations S, T, L T. L